Keywords: fluvastatin, slows, cad, development, lcas, sandoz, hmg-coa

Fluvastatin Slows CAD Development; LCAS

Article | 25 November 1996

Sandoz' HMG-CoA reductase inhibitor Lescol (fluvastatin) can regress or slow progression of atherosclerosis in patients with coronary artery disease and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Sandoz

Go to company listing

Related Drugs

Fluvastatin Sodium

Lescol

Go to drug listing